MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hagiwara, M.
Right arrow Articles by Hidaka, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hagiwara, M.
Right arrow Articles by Hidaka, H.

Specific binding of a novel compound, N-[2-(methylamino)ethyl]-5- isoquinolinesulfonamide (H-8) to the active site of cAMP-dependent protein kinase

M Hagiwara, M Inagaki and H Hidaka

The interaction of the catalytic subunit of bovine cardiac muscle cAMP- dependent protein kinase with N-[2-(methylamino)ethyl]-5- isoquinolinesulfonamide (H-8), the most potent and selective inhibitor toward cyclic nucleotide-dependent protein kinases in the series of isoquinolinesulfonamide derivatives, was studied. The addition of H-8 protected the catalytic subunit of the enzyme in a dose-dependent manner from irreversible inactivation by the ATP analogue p- fluorosulfonylbenzoyl-5'-adenosine (FSBA). The inactivation followed pseudo-first order kinetics and H-8 reduced the steady state constant of inactivation (Ki) without any effect on the first order rate constant (K3). The quantitative binding of H-8 to the enzyme was measured under conditions of thermodynamic equilibrium using a gel filtration method. The catalytic subunit bound approximately 1 mol of drug/mol of protein with apparent half-maximal binding at 1.0 microM drug, whereas the enzyme irreversibly modified by FSBA did not bind the drug, confirming that the enzyme has no site for H-8 in the catalytic subunit other than the active site. The binding studies also showed that H-8 does not require divalent cations such as Mg2+ to bind to the catalytic subunit of the protein kinase. The binding of H-8 to the active site was characterized using FSBA and other affinity labeling reagents which have been postulated to modify residues at or near the active site of the catalytic subunit. H-8 protected the enzyme against inactivation by FSBA and Cibacron Blue F3GA but did not afford any protection against the covalent modification of 5,5'-dithiobis-(2- nitrobenzoic acid) (DTNB) and 7-chloro-4-nitro-2,1,3-benzoxadiazole (NBD-Cl), suggesting that the binding site of H-8 does not involve the gamma-subsite of the ATP binding site in the catalytic subunit, since DTNB and NBD-Cl are thought to modify the residues complementary to gamma-phosphate of the ATP molecules.

Volume 31, Issue 5, pp. 523-528, 05/01/1987
Copyright © 1987 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Muraki, B. Ohkawara, T. Hosoya, H. Onogi, J. Koizumi, T. Koizumi, K. Sumi, J.-i. Yomoda, M. V. Murray, H. Kimura, et al.
Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks
J. Biol. Chem., June 4, 2004; 279(23): 24246 - 24254.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
I L P Beales and J Calam
Inhibition of carbachol stimulated acid secretion by interleukin 1{beta} in rabbit parietal cells requires protein kinase C
Gut, June 1, 2001; 48(6): 782 - 789.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
K. A. Volk, R. F. Husted, P. M. Snyder, and J. B. Stokes
Kinase regulation of hENaC mediated through a region in the COOH-terminal portion of the alpha -subunit
Am J Physiol Cell Physiol, May 1, 2000; 278(5): C1047 - C1054.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Santicioli and C. A. Maggi
Myogenic and Neurogenic Factors in the Control of Pyeloureteral Motility and Ureteral Peristalsis
Pharmacol. Rev., December 1, 1998; 50(4): 683 - 722.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. R. Young, M. M. McLaughlin, S. Kumar, S. Kassis, M. L. Doyle, D. McNulty, T. F. Gallagher, S. Fisher, P. C. McDonnell, S. A. Carr, et al.
Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site
J. Biol. Chem., May 2, 1997; 272(18): 12116 - 12121.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
C. A. Gebert, S.-H. Park, and D. J. Waxman
Regulation of Signal Transducer and Activator of Transcription (STAT) 5b Activation by the Temporal Pattern of Growth Hormone Stimulation
Mol. Endocrinol., April 1, 1997; 11(4): 400 - 414.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
R. A. Engh, A. Girod, V. Kinzel, R. Huber, and D. Bossemeyer
Crystal Structures of Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Isoquinolinesulfonyl Protein Kinase Inhibitors H7, H8, and H89. STRUCTURAL IMPLICATIONS FOR SELECTIVITY
J. Biol. Chem., October 18, 1996; 271(42): 26157 - 26164.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1987 by the American Society for Pharmacology and Experimental Therapeutics